Health & Environmental Research Online (HERO)


Print Feedback Export to File
3748772 
Journal Article 
Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors 
Olsen, GW; Church, TR; Miller, JP; Burris, JM; Hansen, KJ; Lundberg, JK; Armitage, JB; Herron, RM; Medhdizadehkashi, Z; Nobiletti, JB; O'Neill, EM; Mandel, JH; Zobel, LR 
2003 
Yes 
Environmental Health Perspectives
ISSN: 0091-6765
EISSN: 1552-9924 
US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE 
RES TRIANGLE PK 
111 
16 
1892-1901 
English 
Perfluorooctanesulfonyl fluoride-based products have included surfactants, paper and packaging treatments, and surface protectants (e.g., for carpet, upholstery, textile). Depending on the specific functional derivatization or degree of polymerization, such products may degrade or metabolize, to an undetermined degree, to perfluorooctanesulfonate (PFOS), a stable and persistent end product that has the potential to bioaccumulate. In this investigation, a total of 645 adult donor serum samples from six American Red Cross blood collection centers were analyzed for PFOS and six other fluorochemicals using HPLC-electrospray tandem mass spectrometry. PFOS concentrations ranged from the lower limit of quantitation of 4.1 ppb to 1656.0 ppb with a geometric mean of 34.9 ppb [95% confidence interval (CI), 33.3-36.5]. The geometric mean was higher among males (37.8 ppb; 95% CI, 35.5-40.3) than among females (31.3 ppb; 95% CI, 30.0-34.3). No substantial difference was observed with age. The estimate of the 95% tolerance limit of PFOS was 88.5 ppb (upper limit of 95% CI, 100.0 ppb). The measures of central tendency for the other fluorochemicals (N-ethyl perfluorooctanesulfonamidoacetate, N-methyl perfluorooctanesulfonamidoacetate, perfluorooctanesulfonamidoacetate, perfluorooctanesulfonamide, perfluorooctanoate, and perfluorohexanesulfonate) were approximately an order of magnitude lower than PFOS. Because serum PFOS concentrations correlate with cumulative human exposure, this information can be useful for risk characterization. 
American Red Cross; biomonitoring; blood donors; fluorochemicals; perfluorooctanesulfonate; perfluorooctanoate; PFOA; PFOS 
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          PubMed
          Web of Science
          Other Sources
               Reference list review of included studies
     Screened Studies
          Supplemental
     2-(N-Methylperfluorooctanesulfonamido)acetate
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
     Not prioritized for screening
     Perfluorooctane
     Ethyl perfluorooctanoate
     2-(N-Methylperfluorooctanesulfonamido)acetate
• NMeFOSAA
     Literature Search
          Pubmed
          WOS
     Screening Results
          Excluded/Not on Topic
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFHxS (355-46-4)
          Literature search
               Pubmed
               WOS
     PFOSA (754-91-6)
          Literature Search
               Pubmed
               WOS
     NMeFOSAA (2355-31-9)
          Literature Search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
          Other sources
               ECHA
     Screened Studies
          Supplemental
     Ammonium perfluorooctanoate
     Perfluorooctane
     Perfluorooctanesulfonamide
     Perfluorooctanesulfonate
     Perfluorooctanesulfonic acid
     Perfluorooctanesulfonyl fluoride
• PFBA
     Protocol References
• PFHxS
     Database searches
          Pubmed
          Toxline
          WOS
          Scopus
     Excluded
          TiAb
• PFOSA
     Literature Search
          Pubmed
          WOS
     Screening Results
          Susceptible populations